Volume : 10, Issue : 02, February – 2023

Title:

47.DEVELOPING AND ASSESSING BUCCAL PATCHES WITH ANTI-DIABETIC DRUG
‬

Authors :

Medapati Ramya Sri, L.Devakmma

Abstract :

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes. The present investigation is concerned with the development of the metformin HCl buccal films, which were designed to prolong the buccal residence time, to increase penetration through buccal mucosa and thus increase the bioavailability and its half-life. Various formulations were developed by using release rate controlling film forming polymers like HPMC 5cps and HPMC 50cps in various combinations using plasticizer PEG 400. The prepared films were evaluated for number of parameters like physical appearance and surface texture, weight uniformity, thickness of the films, folding endurance, swelling index, tensile strength, drug excipients interaction study, content uniformity, in-vitro drug release study. The FTIR studies indicate that Metformin HCl showed complete entrapment within the polymer carrier bonding is suggested and there was no chemical interaction. From all the formulations, F8 shows maximum drug release at the ends of 8 hr and chosen as optimized formulation and which follows zero order release with super case II transport mechanism.
Keywords: Metformin HCl, HPMC, FTIR, super case II transport.

Cite This Article:

Number of Downloads : 10

References:

[1] Shidhaye SS, et al. Mucoadhesive bilayered patches for administration of sumatriptan. AAPS pharm sci tech. 2009; 9(3): 1-13.
[2] Giradkar KP, et al. Design development and in vitro evaluation of bioadhesive dosage form for buccal route. International journal of pharma research & development. 2010; 2: 1-24.
[3] Amir H, et al. Systemic drug delivery via the buccal mucosal route, Pharmaceutical technology. 2001; 1-27.
[4] Fatima AA, Chukwuka UK. Development and in-vitro evaluation of matrix-type transdermal patches of losartan potassium. Universal Journal of Pharmaceutical Research. 2017; 2(2): 16-20.
[5] Steward A, et al. The Effect of Enhancers on the Buccal Absorption of Hybrid (BDBB) Alpha-Interferon.IntJ Pharm. 1994; 104: 145–149.
[6] Al-kaf AGA, Othman AM. Pharmacosomes: an Updated review, Universal Journal of Pharmaceutical Research. 2017; 2(1): 30-33.
[7] Mishra S. A Review articl: Recent Approaches in buccal patches, the pharma innovation. 2012;7(2):78-86.
[8] AJ Hoogstraate, et al. Diffusion Rates and Transport Pathways of FITC-Labelled Model Compounds through Buccal Epithelium, Proc. Int. Symp. Contr. Rel. Bioact.Mater. 1993;20:234–235.
[9] Bhartee P, Kapil Kumar. Buccal drug delivery system: a tool for the effective delivery of pharmaceuticals. Universal Journal of Pharmaceutical Research. 2017; 2(3): 19-24.
[10] Ryan FD, Paul AM, Agnieszka AZ, David W. Design and physicochemical characterization of a bioadhesive patch for dose controlled topical delivery of imiquimod. Int J Pharm. 2006;307:3 18-25. [11] Shafiullah D, Pramodkumar TM, Shivakumar HG. Formulation and evaluation of chlorhexidine mucoadhesive drug delivery systems. Ind Drugs. 2006;43(2): 122-5.
[12] Diojad RC, Manvi FV, Malleshwarrao VSN, Patel PS. Buccoadhesive drug delivery system of isosorbide dinitrate: Formulation and evaluation. Ind J Pharm Sci. 2006;68(6):744-8.